Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.38 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13598970 | 0.86 | OPRM1 (0.50) | OPRM1OPRD1OPRK1OPRL1BDKRB2 | |
| SCHEMBL16838113 | 0.81 | NPSR1 (0.32) | OPRM1OPRD1OPRK1OPRL1NPSR1 | |
| SCHEMBL8372902 | 0.80 | KMT2A (0.34) | OPRM1OPRD1OPRK1BDKRB2SLC6A4 | |
| SCHEMBL14400310 | 0.79 | KDM4E (0.37) | OPRM1OPRD1OPRK1OPRL1CCR1 | |
| SCHEMBL383477 | 0.79 | NCF1 (0.33) | OPRM1OPRD1OPRK1OPRL1NPSR1 | |
| SCHEMBL129415 | 0.79 | — | — | |
| SCHEMBL25571576 | 0.77 | NPSR1 (0.41) | CCR1CHRM2CHRM3NPSR1GAA | |
| SCHEMBL7839577 | 0.76 | OPRM1 (0.45) | OPRM1OPRD1OPRK1OPRL1SLC6A4 | |
| SCHEMBL21976648 | 0.76 | OPRM1 (0.32) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL18562537 | 0.76 | CCR1 (0.31) | CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649248-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2023-05-16 | — | — | US | disclosed |
| WO-2023067560-A1 | IONIZABLE CATIONIC COMPOUND | Seqirus Inc. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20210236474-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AS LSD-1 INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2021-08-05 | — | — | US | disclosed |
| US-8828996-B2 | Morpholine-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-09 | — | — | US | disclosed |
| US-20120264749-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-10-18 | — | — | US | disclosed |
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-7998958-B2 | Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors | SCHERING CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| US-7763613-B2 | Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors | SCHERING CORPORATION (US) | 2010-07-27 | — | — | US | disclosed |
| US-20100093695-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | SCHERING CORP. | 2010-04-15 | — | — | US | disclosed |
| US-20100087425-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | SCHERING CORP. | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236474-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AS LSD-1 INHIBITORS | KDM1A, KDM4A, KDM1B | OPRM1 611/4885OPRD1 1317/4885OPRK1 639/4885 |
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | OPRM1 2032/4885OPRD1 2809/4885OPRK1 1227/4885 |
| US-20100093695-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | BACE1, BACE2, APP | OPRM1 1498/4885OPRD1 406/4885OPRK1 1037/4885 |
| US-11649248-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | OPRD1, OPRM1, OPRK1 | OPRM1 2/4885OPRD1 1/4885OPRK1 3/4885 |
| US-20100087425-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | BACE1, BACE2, APP | OPRM1 1522/4885OPRD1 412/4885OPRK1 1081/4885 |
| US-20120264749-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPM5, KCNQ1 | OPRM1 425/4885OPRD1 258/4885OPRK1 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.